/Company Directory

/

Asset Brief

Bisantrene

RAC·Racura Oncology·Liposarcoma (soft tissue cancer arising from fat cells)·Phase 2·[ TODO: fill in ]

Plain-language Brief

The trial in plain terms

The disease: Liposarcoma is a malignant tumour that develops from fat tissue and is one of the more common subtypes of soft tissue sarcoma. It can arise in various sites in the body, most often the extremities and retroperitoneum (the space behind the abdominal cavity). Treatment options are limited, particularly for patients whose disease has returned or not responded to prior therapy. There is no dedicated trial record in the provided data linking bisantrene to liposarcoma, so specific programme details cannot be confirmed from the information supplied.
What the asset is trying to do: Bisantrene is a small molecule that was originally developed as an anthracycline-class antitumour agent. It is understood to interact with DNA, interfering with cancer cell replication, though no detailed mechanism description has been provided in the source data for this specific programme. The available trial registrations for bisantrene on ClinicalTrials.gov are in acute myeloid leukaemia (AML) and related blood cancers, not in liposarcoma.
Efficacy benchmarks in this setting: In soft tissue sarcoma, including liposarcoma, approved second-line or later therapies provide context for this setting. For example, eribulin (Halaven) was approved in the US for liposarcoma based on a Phase 3 trial that showed a median overall survival (OS) of 15.6 months versus 8.4 months for dacarbazine (per Schoffski et al, Lancet 2016, NCT01327885). Trabectedin (Yondelis) is approved in the EU for soft tissue sarcoma and showed a median progression-free survival of 3.3 months versus 1.5 months for dacarbazine in a Phase 3 trial (per Demetri et al, Journal of Clinical Oncology 2016). Any early-stage figures generated by bisantrene in liposarcoma would be from a different patient population and study design and are not statistically comparable to these approved-therapy results.
Commercial context: Racura Oncology (ASX: RAC) disclosed that it raised A$34.3 million to advance three oncology trials (per ASX announcement, 16 June 2026). The company's most recently announced clinical milestone relates to a lung cancer trial called HARNESS-1, for which the first patient was treated in June 2026 (per ASX announcement, 24 June 2026). No regulatory approval exists specifically for bisantrene in liposarcoma. No deal terms, licensing agreements, or manufacturing disclosures specific to the liposarcoma programme have been identified in the data provided. The lead-asset status of bisantrene in liposarcoma within Racura's pipeline cannot be confirmed from available data.

Sources for this brief (7)

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial · The Lancet · accessed 26 June 2026
Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial · Journal of Clinical Oncology · accessed 26 June 2026
Bisantrene Combination for Resistant AML (NCT04989335) · ClinicalTrials.gov · accessed 26 June 2026
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (NCT05456269) · ClinicalTrials.gov · accessed 26 June 2026
Bisantrene for Relapsed/Refractory AML (NCT03820908) · ClinicalTrials.gov · accessed 26 June 2026
Racura raised $34.3m to Advance Three Oncology Trials · ASX / Racura Oncology · accessed 26 June 2026

Trial Design

Design summary

Phase: Phase 2
Design type: [ TODO: fill in ] No liposarcoma trial registration for bisantrene has been identified in the provided data.
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: [ TODO: fill in ]
Current enrolment status: [ TODO: fill in ]
Sites: [ TODO: fill in ]
Expected readout window: [ TODO: fill in ] No primary completion date can be inferred without a liposarcoma-specific trial registration.

Asset Track Record

Did RAC deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

2 July 2026regulatory decisionRC220 (E,E-bisantrene) Bellberry Human Research Ethics Committee (HREC) — Bellberry Ethics Approval Activates New HARNESS Trial Siteshit · positivesrc ASX ↗
24 June 2026otherRC220 (E,E-bisantrene) (HARNESS-1) — Racura Treats First Patient in HARNESS-1 Lung Cancer Trialhit · positivesrc ASX ↗
16 June 2026otherRacura raised $34.3m to Advance Three Oncology Trialshitsrc ASX ↗
3 June 2026financingProposed issue of securities - RAChitsrc ASX ↗
3 June 2026otherEmerging Companies Specialist Invests in Racurahitsrc ASX ↗
31 May 2026data readoutBisantrene Phase 1/2 AML interim dataoverdue
29 May 2026commercial milestonePiggyback Options Expirationhitsrc ASX ↗
28 May 2026otherRacura Enters Underwriting Agreement for Optionshitsrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for Bisantrene and peers

Bisantrene's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Bisantrene. Showing past 6 months and next 12 months · 6 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
ConferenceESMO Congress 2026

Trial design comparison

How Bisantrene reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
Bisantrene	Racura Oncology	Small Molecule Other	Phase 2[ TODO: fill in ]	[ TODO: fill in ] No liposarcoma trial registration for bisantrene has been identified in the provided data.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

37 activeexpand ›

SA
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Phase 3
Sarcoma Alliance for Research through Collaboration·Active, not recruiting·Primary completion 1 Dec 2025·NCT04967521
9 sites·4 top centres: Mayo Clinic, Northwestern, +2

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for Bisantrene yet. Broker coverage of Racura Oncology is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Asset Track Record

Did RAC deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

2 July 2026regulatory decisionRC220 (E,E-bisantrene) Bellberry Human Research Ethics Committee (HREC) — Bellberry Ethics Approval Activates New HARNESS Trial Siteshit · positivesrc ASX ↗
24 June 2026otherRC220 (E,E-bisantrene) (HARNESS-1) — Racura Treats First Patient in HARNESS-1 Lung Cancer Trialhit · positivesrc ASX ↗
16 June 2026otherRacura raised $34.3m to Advance Three Oncology Trialshitsrc ASX ↗
3 June 2026financingProposed issue of securities - RAChitsrc ASX ↗
3 June 2026otherEmerging Companies Specialist Invests in Racurahitsrc ASX ↗
31 May 2026data readoutBisantrene Phase 1/2 AML interim dataoverdue
29 May 2026commercial milestonePiggyback Options Expirationhitsrc ASX ↗
28 May 2026otherRacura Enters Underwriting Agreement for Optionshitsrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for Bisantrene and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
ConferenceESMO Congress 2026

Trial design comparison

How Bisantrene reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
Bisantrene	Racura Oncology	Small Molecule Other	Phase 2[ TODO: fill in ]	[ TODO: fill in ] No liposarcoma trial registration for bisantrene has been identified in the provided data.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

37 activeexpand ›

SA
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Phase 3
Sarcoma Alliance for Research through Collaboration·Active, not recruiting·Primary completion 1 Dec 2025·NCT04967521
9 sites·4 top centres: Mayo Clinic, Northwestern, +2

Bisantrenen = 0

Racura Oncology·Small Molecule Other·Phase 2·[ TODO: fill in ]

Design: [ TODO: fill in ] No liposarcoma trial registration for bisantrene has been identified in the provided data.
Primary endpoint: [ TODO: fill in ]
Dosing: [ TODO: fill in ]
Eligibility: [ TODO: fill in ]

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoman = —

Sarcoma Alliance for Research through Collaboration·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoman = —

European Organisation for Research and Treatment of Cancer - EORTC·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinismn = —

Rezolute·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomasn = —

National Cancer Institute (NCI)·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgeryn = —

National Cancer Institute (NCI)·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)n = —

Fox Chase Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoman = —

USWM CT, LLC·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoman = —

USWM, LLC (dba US WorldMeds)·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumorsn = —

USWM CT, LLC·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoman = —

USWM CT, LLC·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoman = —

HRYZ Biotech Co.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoman = —

National Cancer Institute LAO·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Palbociclib and INCMGA00012 in People With Advanced Liposarcoman = —

Memorial Sloan Kettering Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

First-line Treatment of Advanced/unresectable DDLPSn = —

Fudan University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoman = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of Abemaciclib in Dedifferentiated Liposarcoman = —

Memorial Sloan Kettering Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumorsn = —

Pfizer·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgeryn = —

National Cancer Institute (NCI)·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

APX005M and Doxorubicin in Advanced Sarcoman = —

Alexander Z. Wei, MD·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoman = —

Memorial Sloan Kettering Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoman = —

Alliance for Clinical Trials in Oncology·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgeryn = —

M.D. Anderson Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)n = —

Fudan University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)n = —

Lund University Hospital·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Pembrolizumab in People With Ultra-Rare Sarcomasn = —

Memorial Sloan Kettering Cancer Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.n = —

Oslo University Hospital·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoman = —

Oslo University Hospital·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumorsn = —

Sotio Biotech Inc.·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumorsn = —

Lamassu Bio Inc·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumorsn = —

Ascentage Pharma Group Inc.·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.n = —

Shanghai Pharmaceuticals Holding Co., Ltd·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoman = —

National Cancer Institute (NCI)·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomasn = —

STORM Therapeutics LTD·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patientsn = —

Grupo Espanol de Investigacion en Sarcomas·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoman = —

Memorial Sloan Kettering Cancer Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumorsn = —

Milton S. Hershey Medical Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)n = —

St. Jude Children's Research Hospital·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —